文献速递免疫规划慢病防控与筛查

实体癌患者对SARS-CoV-2疫苗体液免疫应答的决定因素:系统综述与荟萃分析

Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2023-02-13

该系统综述与荟萃分析检索MEDLINE、Embase、Web of Science、Cochrane Library和ClinicalTrials.gov至2022年5月1日,纳入15项研究3593例实体癌患者,比较接种COVID-19疫苗后抗SARS-CoV-2刺突蛋白受体结合域应答者与非应答者。汇总血清转化率为84%,男性、年龄>65岁和近期化疗与不良免疫应答相关,随访中、接受免疫治疗或靶向治疗的患者更可能血清阳性。

要点

  • 实体癌患者接种COVID-19疫苗后汇总血清转化率为84%。
  • 男性、年龄>65岁和近期化疗是不良免疫应答的相关因素。
  • 免疫治疗或靶向治疗与血清阳性相关,癌种、疫苗类型和抗体检测时间与血清转化无关。

核心结论

  • 实体癌的细胞毒性治疗可能预示接种2剂COVID-19疫苗后免疫应答不佳,提示这些患者需要加强针。
  • 免疫治疗和靶向治疗可能与小血清阳性状态相关,因此在两者疗效相当时可考虑作为细胞毒性药物的替代方案。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science、Cochrane Library和ClinicalTrials.gov至2022年5月1日。
  • 纳入前瞻性或回顾性研究,比较接种COVID-19疫苗后抗SARS-CoV-2刺突蛋白受体结合域应答者与非应答者。
  • 共纳入15项研究,3593例患者。

主要发现

  • 汇总研究人群的血清转化率为84%。
  • 男性、年龄>65岁和近期化疗均为不良免疫应答的因素。
  • 随访中患者、接受免疫治疗或靶向治疗的患者更可能血清阳性。
  • 癌种亚型、疫苗类型和距第2剂疫苗抗体检测时间与血清转化无关。

关键数值与推荐

  • 二分类变量计算汇总比值比(pOR)及95%CI,连续变量计算均值差(含标准差)。

临床怎么用

  • 作者认为细胞毒性治疗可能预示接种2剂COVID-19疫苗后免疫应答不佳,提示这些患者需要加强针。
  • 作者认为免疫治疗和靶向治疗可能与小血清阳性状态相关,在两者疗效相当时可考虑作为细胞毒性药物的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Solid cancer patients following SARS-CoV-2 vaccination are likely to have a lower seroconversion rate than healthy adults. Seroconversion between those with and without cancer is likely to vary moderately or to be restricted to specific subgroups. Therefore, we sought to conduct a systematic review and meta-analysis to identify risk factors for diminished humoral immune responses in solid cancer patients. METHODS: MEDLINE, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov were used to search literature through May 1, 2022. Prospective or retrospective studies comparing responders with non-responders against SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) following COVID-19 vaccination were included. Pooled Odds Ratios (pORs) with 95% CIs for binary variables and differences in means (with SDs) for continuous variables were calculated to determine the pooled effect estimates of risk factors for poor antibody response. RESULTS: Fifteen studies enrolling 3593 patients were included in the analysis. Seroconversion was seen in 84% of the pooled study population. Male gender, age >65 years, and recent chemotherapy were all factors in a poor immune response. Patients under follow-up, those who received immunotherapy or targeted therapy, were more likely to be seropositive. Cancer subtypes, vaccine types, and timing of antibody testing from the 2nd dose of vaccine did not correlate with seroconversion. CONCLUSION: Cytotoxic therapy for solid cancer may portend poor immune response following 2 doses of COVID-19 vaccines suggesting a need for booster doses in these patients. Immunotherapy and targeted therapy are likely to be associated with seropositive status, and thus can be considered as an alternative to cytotoxic agents in cases where both therapies are equally efficacious.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wankhede D, Grover S, Hofman P, et al. Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis. Vaccine. 2023. PMID: 36792435. doi:10.1016/j.vaccine.2023.01.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。